Patents by Inventor Galit HORN

Galit HORN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230321235
    Abstract: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.
    Type: Application
    Filed: August 11, 2021
    Publication date: October 12, 2023
    Applicants: Yeda Research and Development Co. Ltd., Ichilov Tech Ltd.
    Inventors: Yair REISNER, Anat GLOBERSON LEVIN, Esther BACHAR-LUSTIG, Assaf LASK, Bar NATHANSOHN-LEVI, Tova WAKS, Galit HORN, Zelig ESHHAR
  • Publication number: 20230167158
    Abstract: The present invention discloses a fusion protein comprising a vesicular stomatitis virus envelope glycoprotein (VSVG) extracellular domain or a fragment or an analog thereof linked to a polypeptide comprising an antigen binding domain specific to cluster of differentiation 3 (CD3). The application also discloses pseudotyped viruses comprising the fusion protein and pseudotyped viruses encoding for a chimeric antigen receptor (CAR) or T-cell receptor pseudotyped in which the receptor is expressed under a CD3 promoter. Pseudotyped viruses combining these properties are encompassed as well. The application further discloses use of these pseudotyped viruses and method of producing these pseudotyped viruses.
    Type: Application
    Filed: January 12, 2023
    Publication date: June 1, 2023
    Inventors: Amer M NAJJAR, Anat GLOBERSON LEVIN, Tova WAKS, Galit HORN
  • Publication number: 20220204928
    Abstract: The present invention provides extracellular vesicles (EVs) derived from T-cells expressing chimeric antigen receptors (CAR) specifically activated with an antigen to which the CAR bind specifically, pharmaceutical compositions comprising these vesicles as well as their use in treating cancer. In particular the present invention exemplifies EVs derived from activated T-cells expressing CAR that bind specifically to HER2 cancer antigen, pharmaceutical composition comprising these EVs and their use in treating a cancer overexpressing HER2, such as ovarian cancer and breast cancer.
    Type: Application
    Filed: April 16, 2020
    Publication date: June 30, 2022
    Inventors: Anat AHARON, Anat GLOBERSON LEVIN, Irit AVIVI, Galit HORN, Tova WAKS, Zelig ESHHAR